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ABSTRACT 
In children and adolescents, growth hormone (GH) and insulin-like growth factor-I (IGF-I) act 
in concert to stimulate linear growth; however, the effects on glucose metabolism are in 
opposition. GH increases insulin resistance by lipolysis. In contrast, IGF-I stimulates glucose 
uptake and downregulates GH secretion, thus improving insulin sensitivity. Children with GH 
receptor mutations , severe primary IGF-I deficiency (PIGFD), lack both the growth-promoting 
and the metabolic effects of GH and IGF-I, and children with type 1 diabetes mellitus (T1DM), 
aquired IGF-I deficiency, have low portal insulin concentrations, increased IGFBP-1 levels, 
hepatic GH insensitivity, low circulating IGF-I, and increased GH secretion, i.e. mechanisms 
that increase insulin resistance and impair metabolic control (HbA1c). The aims of this thesis 
were to study the effects of two different rhIGF-I preparations on growth and metabolism in 
severe PIGFD, and the effects of long-acting insulin glargine and continuous subcutaneous 
insulin infusion (CSII) on the GH/IGF-I axis as well as the direct effects of rhIGF-I on glucose 
disposal and tissue IGF-I levels in T1DM. In Paper I, we studied the effects of rhIGF-
I/rhIGFBP-3 for 17 months and thereafter rhIGF-I for 12 months in two siblings with a GH 
receptor mutation. We found decreased fat mass, increased lean body mass and improved linear 
growth in response to both preparations, although rhIGF-I was clearly more efficient. The data 
on insulin sensitivity (hyperinsulinemic euglycemic clamps) were incongruent. However, 
decreased overnight insulin secretion, most prominent after rhIGF-I, suggested improved 
insulin sensitivity. A diurnal rhythm of circulating IGF-I with higher mean levels and 
suppression of GH secretion was seen on rhIGF-I. In Paper II, an observational study of 12 
adolescents with T1DM, we studied the effects on the GH/IGF-I axis and metabolic control for 
up to 12 weeks after changing from NPH insulin to insulin glargine. We found decreased 
overnight IGFBP-I levels and increased circulating IGF-I levels indicating a more efficient 
nightly insulin delivery thus suggesting improved hepatic insulin sensitivity and improved 
hepatic GH sensitivity which was associated with improved HbA1c.In Paper III, a parallel 
multi-centre study lasting 24 months, 72 children and adolescents with newly diagnosed T1DM 
were randomized to multiple daily insulin injections (MDI) with NPH insulin or CSII and 
studied regarding the effects on the GH/IGF-I axis and endogenous insulin production. We 
found decreased fasting IGFBP-1, indicating a more efficient nightly insulin delivery with CSII 
and thus improved hepatic insulin sensitivity. In addition, the insulin doses were lower in the 
CSII group indicating improved insulin sensitivity. In Paper IV, eight males with T1DM were 
studied in a randomized single-blind, placebo-controlled, cross-over study. We assessed the 
effects of a single subcutaneous rhIGF-I injection (120 µg/kg) or saline, during a 
normoinsulinemic euglycemic clamp, on glucose utilization and tissue levels of IGF-I in muscle 
and subcutaneous fat determined by microdialysis. We found an increase in whole body glucose 
disposal and a concomitant increase in tissue IGF-I levels during the second hour after injection. 
In summary, this thesis demonstrates that rhIGF-I is superior to rhIGF-I/rhIGFBP-3 in 
promoting linear growth and also improves body composition and decreases insulin levels more 
efficiently. A more sustained insulin delivery profile of insulin glargine and CSII improves 
hepatic insulin sensitivity and insulin glargine increases circulating IGF-I and decreases HbA1c, 
and the thesis provides evidence that the microdialysis technique can be used to assess 
biological effects of IGF-I in tissues.  
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